tcc schreef op 14 januari 2021 09:45:
Nu ook geplaatst op de officiele Clinical Trial site:
Recruiting
New
Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
Post-Viral Fatigue Syndrome
Post-Viral Disorder (Disorder)
Covid19
Drug: Ruconest
IMMUNOe Research Centers
Centennial, Colorado, United States
2
Recruiting
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Coronavirus Infections
Drug: Conestat alfa
University Hospital Basel, Division of Internal Medicine
Basel, Switzerland
3
Recruiting
Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Confirmed Coronavirus Disease
Drug: Ruconest
The Valley Hospital
Ridgewood, New Jersey, United States